ZC3H4: A Potential Drug Target and Biomarker (G23211)

Target Name: ZC3H4

NCBI ID: G23211

ZC3H4

ZC3H4: A Potential Drug Target and Biomarker

Zinc finger chromatin-containing proteins (ZFCPs) are a family of non-coding RNAs that play crucial roles in various cellular processes, including DNA replication, gene expression, and chromosomal stability. ZC3H4, also known as Zinc finger CCCH-type containing 4, is a ZFCP that has been identified as a potential drug target or biomarker.

The ZC3H4 protein is composed of a unique zinc finger domain that consists of a series of 19 amino acid residues. This domain is responsible for the protein's unique structure and function. The zinc finger domain is characterized by a specific pattern of amino acid residues, which is typical of other zinc finger proteins.

One of the key features of the ZC3H4 protein is its ability to interact with DNA. This interaction is mediated by the protein's zinc finger domain, which contains a series of electrostatic interactions that can alter the structure and function of the DNA. The zinc finger domain is also known for its ability to form a stable complex with DNA, which may contribute to the protein's ability to interact with DNA in a more stable manner.

In addition to its ability to interact with DNA, the ZC3H4 protein also has been shown to play a role in various cellular processes. For example, the protein has been shown to be involved in DNA replication, gene expression, and cell cycle progression.

The ZC3H4 protein is also of interest as a potential drug target. Due to its involvement in various cellular processes, the ZC3H4 protein may be a useful target for drugs that are designed to modulate these processes. For example, the protein may be a good candidate for drugs that are used to treat cancer, as its involvement in cell cycle progression and DNA replication may make it an attractive target for cancer therapies.

In addition to its potential as a drug target, the ZC3H4 protein is also of interest as a biomarker. The protein has been shown to be expressed in various tissues and cells, including cancer cells, which may make it an attractive target for biomarkers that can be used to diagnose or monitor the spread of cancer.

In conclusion, the ZC3H4 protein is a unique and promising protein that has the potential to be a drug target or biomarker. Its unique zinc finger domain and ability to interact with DNA make it an attractive target for drugs that are designed to modulate these processes. Additionally, the protein's involvement in various cellular processes makes it of interest as a potential biomarker for various diseases. Further research is needed to fully understand the ZC3H4 protein's role in these processes and its potential as a drug or biomarker.

Protein Name: Zinc Finger CCCH-type Containing 4

Functions: RNA-binding protein that suppresses transcription of long non-coding RNAs (lncRNAs) (PubMed:33913806, PubMed:33767452). LncRNAs are defined as transcripts more than 200 nucleotides that are not translated into protein (PubMed:33913806, PubMed:33767452). Together with WDR82, part of a transcription termination checkpoint that promotes transcription termination of lncRNAs and their subsequent degradation by the exosome (PubMed:33913806, PubMed:33767452). The transcription termination checkpoint is activated by the inefficiently spliced first exon of lncRNAs (PubMed:33767452)

The "ZC3H4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZC3H4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets